Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2020-09-08 Investor Presentation
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science présentera les résultats de son étude de phase 3 dans l’asthme sévère au Congrès Annuel International de European Respiratory Society
Investor Presentation Classification · 1% confidence The document is a press release dated September 8, 2020, announcing that AB Science will present the results of its Phase 3 study (AB07015) in severe asthma at the European Respiratory Society (ERS) Annual Congress. It details the presentation time, the abstract selection for an 'ALERT' session, and provides key efficacy data from the study. This content is characteristic of an initial announcement of clinical trial results or scientific findings, often preceding a full regulatory filing or earnings report. It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), or a formal Earnings Release (ER) which typically focuses on standardized financial metrics. Since it is an announcement about scientific data being presented at a major conference, it fits best under the general category of Investor Presentation (IP) or potentially a Regulatory Filing (RNS) if no better fit exists. Given the focus on presenting study results and key data points to investors/the public, 'Investor Presentation' (IP) is the most appropriate classification, as it functions as a presentation of scientific progress, even if delivered via a press release format. It is not an RPA because it contains substantial content (the results summary and key data points), not just an announcement that a report is available.
2020-09-08 French
AB Science présentera les résultats de son étude de phase 2B/3 AB07002 dans les formes progressives de la sclérose en plaques à la 8ème réunion conjointe ACTRIMS-ECTRIMS (MSVirtual2020)
Regulatory Filings Classification · 1% confidence The document is a press release dated September 7, 2020, announcing that results from the company's Phase 2B/3 study (AB07002) on Masitinib for progressive multiple sclerosis will be presented at the joint ACTRIMS-ECTRIMS meeting. It details the presentation title, session, date, and includes quotes from researchers and background information on the drug and the company. This type of announcement, focusing on the release of clinical trial data or presentation at a scientific conference, is characteristic of an Earnings Release (ER) if it were summarizing financial performance, or more specifically, an Investor Presentation (IP) if it were the presentation itself. However, since this is an announcement *about* data being presented at a conference, and it contains significant forward-looking statements and company background, it functions as a general corporate update related to R&D progress. Given the options, it is not a formal financial report (10-K, IR, MRQ), nor a transcript (CT), nor a formal dividend/share action (DIV, SHA, POS). It is an announcement of scientific/clinical progress, which often falls under Investor Presentation (IP) if it's a detailed update, or sometimes Regulatory Filings (RNS) if it's a general disclosure. Since it details key study results and context, it aligns best with an Investor Presentation (IP) which often includes clinical trial updates, or an Earnings Release (ER) if the context was quarterly results. Given the focus is purely on clinical trial data presentation, and it's not the actual presentation slides, it is a high-level announcement. In the context of financial reporting, major clinical updates are often bundled with ERs or treated as significant investor news. Since it's a press release announcing data presentation, and not the actual financial results summary (ER) or the presentation itself (IP), it is a general corporate disclosure. However, because it details the positive results and the significance of the findings, it is more substantial than a simple RNS. It is closest to an Investor Presentation (IP) in content focus (clinical data/strategy), but since it's a press release *announcing* the presentation, it functions as a significant corporate update. Given the options, and the focus on communicating R&D milestones to investors, IP is a strong candidate, but ER often covers major operational milestones alongside financials. Since this is a detailed announcement of positive study results, it serves the function of informing investors about a key development, making it similar to an ER or IP. I will classify it as an Investor Presentation (IP) because the core subject is the presentation of detailed clinical data and its implications, which is a key component of investor materials.
2020-09-07 French
AB Science to present results from its Phase 2B/3 AB07002 study in progressive forms of multiple sclerosis at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting
Investor Presentation Classification · 1% confidence The document is a press release dated September 7, 2020, announcing that AB Science will present results from its Phase 2B/3 study (AB07002) at a major medical conference (MSVirtual2020). It details the presentation title, session, date, and includes quotes from investigators and management regarding the drug (masitinib) and the study's positive findings for progressive multiple sclerosis. This content is characteristic of an initial announcement of clinical trial data or scientific findings, often preceding a formal Earnings Release (ER) or being a standalone update for investors regarding R&D progress. Since it is a specific announcement about clinical data presentation and not a comprehensive financial report (10-K, IR) or a general earnings summary (ER), it fits best as an Investor Presentation (IP) if it were the slides themselves, or more generally, a communication aimed at investors about a key development. Given the options, this is a high-level announcement of scientific progress and data presentation, which is a core component of investor relations material. It is not a formal regulatory filing like 10-K, nor is it a transcript or a formal earnings release focusing on P&L. It is most closely aligned with the type of information shared in an Investor Presentation (IP) or a significant R&D update. However, since it is a press release announcing the *presentation* of data, and not the data itself in presentation format, it functions as a general corporate update. Given the focus on clinical trial results and scientific milestones, 'Investor Presentation' (IP) is the closest fit for the *type* of information being conveyed, even if the format is a press release. If 'RNS' (Regulatory Filings) were used as a catch-all, it would also apply, but IP captures the subject matter better than the general RNS category.
2020-09-07 English
AB Science : De nouvelles recherches indépendantes révèlent que le masitinib a une activité anti-virale in-vitro directe contre le virus SARS-CoV-2 et représente un médicament candidat prometteur dans
Earnings Release Classification · 1% confidence The document is a press release dated September 2, 2020, announcing the publication of preclinical study results regarding the drug masitinib's antiviral activity against SARS-CoV-2. It quotes researchers and summarizes key findings, concluding with forward-looking statements and company information. This format—an announcement of scientific/clinical progress, often referencing external publications (like bioRxiv) or ongoing trials—is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full financial report (10-K, IR), a formal transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Dividend Notice (DIV), it best fits the 'Earnings Release' category, as these announcements often accompany or precede formal earnings reports to highlight key operational/R&D achievements. Given the focus on research results and clinical program updates, ER is the most appropriate fit among the provided options for a significant corporate announcement of this nature. FY 2020
2020-09-02 French
AB Science: New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19
Regulatory Filings Classification · 1% confidence The document is a press release from AB Science SA announcing the publication of preclinical study results regarding their drug masitinib's anti-viral activity against SARS-CoV-2. It details scientific findings, quotes researchers, mentions an ongoing Phase 2 clinical study, and includes standard 'About' sections and forward-looking statements typical of corporate news releases. This content is not a formal regulatory filing like a 10-K, an official Audit Report (AR), a Dividend Notice (DIV), or a specific financial statement. It is an announcement intended for investors and the public regarding scientific progress, which aligns best with a general corporate announcement or news release. Since there is no specific category for 'Press Release' or 'Research Update', and it is not a formal financial report, the most appropriate classification is the general regulatory/announcement fallback, RNS, or potentially an Investor Presentation (IP) if it were structured as slides, but given the format, RNS is safer, although it strongly resembles an Earnings Release (ER) in structure (announcing results). However, ER is usually for financial results. Given the focus on research publication and clinical trial updates, it functions as a significant corporate update. Since it is not a formal financial report, and it is an announcement of research findings, it fits best under the general 'Regulatory Filings' (RNS) category as a broad corporate communication, or potentially 'LTR' if the focus was on legal/regulatory action, but here it's scientific news. Given the context of financial reporting databases, this type of announcement often falls under RNS if it doesn't fit ER, IR, or CAP. I will classify it as RNS as it is a general corporate announcement of new information.
2020-09-02 English
AB Science : Résultats de l'Assemblée Générale Mixte du 31 août 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Résultats de l'Assemblée Générale Mixte du 31 août 2020" (Results of the Combined General Meeting of August 31, 2020). It explicitly details the voting results for numerous resolutions, categorized as 'Résolutions ordinaires' and 'Résolutions extraordinaires', including approvals and rejections. This content directly corresponds to the official results from a shareholder vote at a general meeting. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-09-01 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.